Breaking News Instant updates and real-time market news.

NLNK

NewLink Genetics

$9.00

-1.06 (-10.54%)

, INCY

Incyte

$99.85

1.41 (1.43%)

13:42
01/08/18
01/08
13:42
01/08/18
13:42

NewLink Genetics timelines mostly in-line with prior guidance, says Stifel

Stifel analyst Stephen Willey noted that NewLink Genetics (NLNK) now expects to complete the majority of enrollment in the Indigo301 melanoma trial by year-end, versus its previous expectation to complete enrollment in 2018, which he said is likely due to additional time required for dose optimization of the novel indoximod salt formulation. The remainder of the 2018 calendar the company laid out is full of mostly expected catalysts and in-line with prior guidance, said Willey, who still expects NewLink to remain levered to Incyte's (INCY) date from the Phase 3 ECHO-301 trial. Willey keeps a Buy rating on NewLink shares.

NLNK

NewLink Genetics

$9.00

-1.06 (-10.54%)

INCY

Incyte

$99.85

1.41 (1.43%)

  • 18

    Jan

  • 25

    Jan

NLNK NewLink Genetics
$9.00

-1.06 (-10.54%)

10/13/17
BOFA
10/13/17
INITIATION
Target $22
BOFA
Buy
NewLink Genetics initiated with a Buy at BofA/Merrill
BofA/Merrill analyst Ying Huang initiated NewLing Genetics with a Buy and $22 price target saying shares are undervalued. The analyst said Newlink is focused on development of indoximod, an IDO pathway inhibitor, which could become a "backbone" therapy for cancer treatment.
10/13/17
10/13/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Visa (V) and MasterCard (MA) were initiated with an Overweight at Stephens. 2. Acuity Brands (AYI) initiated with a Sector Weight at KeyBanc. 3. Williams-Sonoma (WSM) and RH (RH) were initiated with a Hold at Stifel. 4. Signature Bank (SBNY) assumed with a Neutral at Piper Jaffray. 5. NewLink Genetics (NLNK) initiated with a Buy at BofA/Merrill. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/03/17
STFL
11/03/17
NO CHANGE
Target $25
STFL
Buy
NewLink Genetics price target lowered to $25 from $29 at Stifel
Stifel analyst Stephen Willey trimmed his price target on NewLink Genetics (NLNK) to $25 from $29 to reflect incremental dilution from its recent equity fundraising and forecast for increased operating expenses given that the company will soon initiate its pivotal Phase 3 melanoma trial. The analyst, who expects NewLink shares to remain sensitive to near-term data points on the IDO inhibitor front from Bristol-Myers (BMY) and the partnership of Incyte (INCY) and Merck (MRK), keeps a Buy rating on NewLink shares.
11/30/17
GABE
11/30/17
NO CHANGE
Target $133
GABE
Buy
Incyte a top biotech pick for 2018 at Gabelli
Gabelli analyst Jing He highlighted Incyte as his top biotech pick for 2018 telling investors shares are undervalued and should benefit from the Epa melanoma data readout in first half 2018. The analyst said shares are trading near a 52-week low despite progress in the pipeline and believes competitors Bristol-Myers (BMY) and NewLink's (NLNK) IDO inhibitors are a few years behind Epa in development. Further, as tax reform gains more clarity, He believes M&A oncology deals could pickup and views Incyte as an attractive takeover target. Jing He rates Incyte a Buy with a $133 price target.
INCY Incyte
$99.85

1.41 (1.43%)

01/02/18
RBCM
01/02/18
UPGRADE
RBCM
Outperform
Incyte upgraded to Outperform from Sector Perform at RBC Capital
01/02/18
RBCM
01/02/18
UPGRADE
RBCM
Outperform
Incyte upgraded to Outperform at RBC Capital on improved risk-reward
As reported earlier, RBC Capital analyst Brian Abrahams upgraded Incyte to Outperform from Sector Perform. Abrahams says the 31% decline in the stock price from the September high makes for more substantially improved risk-reward profile as expectations for the phase 3 epa melanoma readout have come down. The analyst says he remains bullish on the long-term growth prospects for Jakafi, modeling its undiscounted, taxed cash flows through end-2026 patent expiry of about $14B.
01/02/18
OPCO
01/02/18
NO CHANGE
Target $120
OPCO
Perform
Incyte price target lowered to $120 from $135 at Oppenheimer
Oppenheimer analyst Jay Olson lowered his price target for Incyte to $120 from $135, citing share underperformed following the presentation of updated ECHO-202 data for epacadostat+Keytruda in advanced melanoma at ESMO. The analyst believes the Incyte share price decline was driven by loss of M&A premium as investors became disappointed by limited Biotech deal activity, concern about potential share price impact of ECHO-301 results in 1H18, and nervousness about the data at ESMO. Olson reiterates an Perform rating on the shares.
01/08/18
DBAB
01/08/18
NO CHANGE
Target $110
DBAB
Buy
Celgene deal 'incremental negative' for Incyte, says Deutsche Bank
Deutsche Bank analyst Navin Jacob calls Celgene's (CELG) acquisition of Impact Biomedicines "one step" in the right direction. The analyst estimates Impact's Jak2 inhibitor fedratinib can achieve 20% of peak Jakafi sales in myelofibrosis and polycythemia vera, which translates to $1B. The asset fits Celgene's business and the $2.4B that the company is paying over the next two years "doesn't appear egregious for a commercial ready asset," Jacob tells investors in a research note. The analyst also views Celgene's acquisition as an "incremental negative" for Incyte (INCY). Given direct overlap, any future potential acquisition of Incyte by Celgene has been removed, Jacob contends. He keeps a Hold rating on Celgene with a $110 price target.

TODAY'S FREE FLY STORIES

NCR

NCR Corp.

$31.30

0.11 (0.35%)

05:49
05/22/18
05/22
05:49
05/22/18
05:49
Conference/Events
NCR Corp. management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

, PFE

Pfizer

$35.79

0.15 (0.42%)

05:44
05/22/18
05/22
05:44
05/22/18
05:44
Hot Stocks
Spark Therapeutics, Pfizer announce data SPK-9001 ongoing Phase 1/2 trial »

Spark Therapeutics (ONCE)…

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

PFE

Pfizer

$35.79

0.15 (0.42%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 05

    Jun

  • 10

    Sep

FMC

FMC Corporation

$91.30

-0.22 (-0.24%)

05:41
05/22/18
05/22
05:41
05/22/18
05:41
Hot Stocks
FMC Corporation awarded contract for two fertilizer plants in India »

TechnipFMC, in consortium…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

S

Sprint

$5.17

0.05 (0.98%)

05:40
05/22/18
05/22
05:40
05/22/18
05:40
Hot Stocks
Sprint partners with Scopeworker on multi-billion dollar 5G depoloyment »

Scopeworker announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSHD

Goosehead Insurance

$16.19

0.12 (0.75%)

05:39
05/22/18
05/22
05:39
05/22/18
05:39
Initiation
Goosehead Insurance initiated  »

Goosehead Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SMAR

Smartsheet

$20.00

0.14 (0.70%)

05:38
05/22/18
05/22
05:38
05/22/18
05:38
Initiation
Smartsheet initiated  »

Smartsheet initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 04

    Jun

VLRS

Volaris

$5.42

-0.05 (-0.91%)

05:19
05/22/18
05/22
05:19
05/22/18
05:19
Recommendations
Volaris analyst commentary  »

Volaris price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BAX

Baxter

$72.08

1.4603 (2.07%)

05:16
05/22/18
05/22
05:16
05/22/18
05:16
Recommendations
Baxter analyst commentary  »

Baxter buybacks should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOCU

DocuSign

$43.06

-1.73 (-3.86%)

05:08
05/22/18
05/22
05:08
05/22/18
05:08
Initiation
DocuSign initiated  »

DocuSign initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

AROC

Archrock

$12.30

0.35 (2.93%)

05:07
05/22/18
05/22
05:07
05/22/18
05:07
Recommendations
Archrock analyst commentary  »

Archrock added to Alpha…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PSTG

Pure Storage

$23.60

-0.065 (-0.27%)

05:05
05/22/18
05/22
05:05
05/22/18
05:05
Recommendations
Pure Storage analyst commentary  »

Pure Storage weakness a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 07

    Jun

  • 12

    Jun

  • 10

    Jul

DOCU

DocuSign

$43.06

-1.73 (-3.86%)

05:02
05/22/18
05/22
05:02
05/22/18
05:02
Initiation
DocuSign initiated  »

DocuSign initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jun

SSL

Sasol

$37.93

0.05 (0.13%)

05:00
05/22/18
05/22
05:00
05/22/18
05:00
Downgrade
Sasol rating change  »

Sasol downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GSHD

Goosehead Insurance

$16.19

0.12 (0.75%)

04:58
05/22/18
05/22
04:58
05/22/18
04:58
Initiation
Goosehead Insurance initiated  »

Goosehead Insurance…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ALG

Alamo Group

$100.36

1.34 (1.35%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Alamo Group management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

ALNA

Allena Pharmaceuticals

$15.99

-0.01 (-0.06%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Allena Pharmaceuticals management to meet with Wedbush »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 23

    May

CTIC

CTI BioPharma

$4.79

-0.1 (-2.05%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
CTI BioPharma management to meet with Oppenheimer »

Meeting to be held in San…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

BAYRY

Bayer

$0.00

(0.00%)

, BDX

Becton Dickinson

$228.74

3.73 (1.66%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
American Thoracic Society to hold a conference »

ATS 2018 will be held in…

BAYRY

Bayer

$0.00

(0.00%)

BDX

Becton Dickinson

$228.74

3.73 (1.66%)

BIIB

Biogen

$277.69

-2.66 (-0.95%)

BSX

Boston Scientific

$30.65

0.19 (0.62%)

CELG

Celgene

$74.69

-3.7 (-4.72%)

DNA

Bought by RHHBY

$0.00

(0.00%)

FGEN

FibroGen

$52.55

1.45 (2.84%)

GSK

GlaxoSmithKline

$40.05

0.005 (0.01%)

HRC

Hill-Rom

$90.70

0.12 (0.13%)

INNV

Innovus Pharmaceuticals

$0.00

(0.00%)

RETA

Reata Pharmaceuticals

$31.86

0.28 (0.89%)

OCX

OncoCyte

$2.50

-0.05 (-1.96%)

VVUS

VIVUS

$0.80

0.0079 (1.00%)

NBRV

Nabriva Therapeutics

$4.54

-0.89 (-16.39%)

MYL

Mylan

$39.55

-0.1 (-0.25%)

MASI

Masimo

$97.75

0.64 (0.66%)

TEVA

Teva

$21.09

-0.14 (-0.66%)

STEM

Ticker changed to MBOT

$0.00

(0.00%)

JAZZ

Jazz Pharmaceuticals

$166.01

-1.59 (-0.95%)

REGN

Regeneron

$296.58

-5.29 (-1.75%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

  • 30

    May

  • 31

    May

  • 03

    Jun

  • 05

    Jun

  • 05

    Jun

  • 13

    Jun

  • 13

    Jun

  • 14

    Jun

  • 16

    Jun

  • 25

    Jun

  • 26

    Jun

  • 11

    Aug

  • 07

    Sep

  • 20

    Oct

  • 13

    Nov

  • 20

    Dec

EXTR

Extreme Networks

$9.16

-0.02 (-0.22%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Extreme Networks management to meet with Needham »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 24

    May

  • 29

    May

EHTH

eHealth

$20.06

0.26 (1.31%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
eHealth management to meet with Craig Hallum »

Meeting to be held in New…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 29

    May

SYF

Synchrony

$35.73

0.29 (0.82%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Synchrony management to meet with RBC Capital »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 30

    May

PES

Pioneer Energy

$6.13

0.275 (4.70%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Pioneer Energy management to meet with Seaport Global »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 23

    May

ATO

Atmos Energy

$85.25

0.37 (0.44%)

, AVA

Avista

$52.62

0.07 (0.13%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
Credit Suisse to hold meetings at AGA Financial Forum »

Credit Suisse Company…

ATO

Atmos Energy

$85.25

0.37 (0.44%)

AVA

Avista

$52.62

0.07 (0.13%)

BKH

Black Hills

$56.34

0.12 (0.21%)

CMS

CMS Energy

$43.96

-0.16 (-0.36%)

CNP

CenterPoint Energy

$25.21

-0.115 (-0.45%)

D

Dominion

$63.71

0.42 (0.66%)

DTE

DTE Energy

$99.96

0.04 (0.04%)

UK

Union Carbide

$0.00

(0.00%)

ED

Consolidated Edison

$73.82

-0.14 (-0.19%)

NI

NiSource

$24.39

-0.05 (-0.20%)

NJR

New Jersey Resources

$43.15

0.3 (0.70%)

NWE

NorthWestern

$53.48

0.26 (0.49%)

SO

Southern Company

$43.42

0.68 (1.59%)

SR

Spire

$70.08

0.4 (0.57%)

SRE

Sempra Energy

$102.64

0.65 (0.64%)

WEC

WEC Energy

$60.20

-0.3 (-0.50%)

XEL

Xcel Energy

$43.55

-0.15 (-0.34%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    May

  • 25

    Jun

ALNY

Alnylam

$100.88

-2.12 (-2.06%)

, SNY

Sanofi

$38.78

-0.09 (-0.23%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
World Federation of Hemophilia to hold a conference »

2018 World Congress of…

ALNY

Alnylam

$100.88

-2.12 (-2.06%)

SNY

Sanofi

$38.78

-0.09 (-0.23%)

BMRN

BioMarin

$89.35

0.4 (0.45%)

BAYRY

Bayer

$0.00

(0.00%)

NVO

Novo Nordisk

$48.70

-0.02 (-0.04%)

PFE

Pfizer

$35.79

0.15 (0.42%)

SHPG

Shire

$169.00

-0.62 (-0.37%)

ONCE

Spark Therapeutics

$73.03

-3.69 (-4.81%)

QURE

uniQure

$31.44

0.08 (0.26%)

DNA

Bought by RHHBY

$0.00

(0.00%)

RHHBY

Roche

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 25

    May

  • 30

    May

  • 05

    Jun

  • 11

    Aug

  • 10

    Sep

  • 12

    Sep

  • 20

    Oct

  • 21

    Dec

  • 28

    Jan

SM

SM Energy

$27.18

0.52 (1.95%)

, APC

Anadarko

$71.69

1.12 (1.59%)

04:55
05/22/18
05/22
04:55
05/22/18
04:55
Conference/Events
JPMorgan to hold a bus tour »

Denver Energy Bus Tour…

SM

SM Energy

$27.18

0.52 (1.95%)

APC

Anadarko

$71.69

1.12 (1.59%)

QEP

QEP Resources

$13.56

0.395 (3.00%)

WLL

Whiting Petroleum

$53.22

1.21 (2.33%)

HK

Halcon Resources

$5.49

-0.08 (-1.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    May

  • 22

    May

  • 13

    Jun

  • 19

    Aug

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.